Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 1:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–7 of 7 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Epidermolysis Bullosa Dystrophica Dominans Clear all
Completed Phase 3 Interventional
View directory record Official record
Conditions
Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
Interventions
Open Label Topical Beremagene Geperpavec (B-VEC)
Biological
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
2 Months and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
6
States / cities
Rancho Santa Margarita, California • Redwood City, California • Coral Gables, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced May 22, 2026, 1:11 AM EDT
Terminated Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Epidermolysis Bullosa Dystrophica, Recessive, Epidermolysis Bullosa Dystrophica, Dominant
Interventions
QR-313, Placebo
Drug
Lead sponsor
Phoenicis Therapeutics
Industry
Eligibility
4 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
4
States / cities
Palo Alto, California • Aurora, Colorado • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced May 22, 2026, 1:11 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
Interventions
Not listed
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
6 Months and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
3
States / cities
Rancho Santa Margarita, California • Redwood City, California • Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced May 22, 2026, 1:11 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
Interventions
Topical Beremagene Geperpavec, Placebo
Biological · Other
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
6 Months and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Rancho Santa Margarita, California • Stanford, California • Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced May 22, 2026, 1:11 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa Dystrophica, Recessive, Epidermolysis Bullosa Dystrophica Dominans
Interventions
Not listed
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
6 Months and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced May 22, 2026, 1:11 AM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
Interventions
KB803, Placebo
Biological · Drug
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
6 Months and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Rancho Santa Margarita, California • Coral Gables, Florida • Worcester, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced May 22, 2026, 1:11 AM EDT
Not listed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Dystrophic Epidermolysis Bullosa
Interventions
PTW-002 10 mg/g gel, Placebo
Drug
Lead sponsor
Phoenicis Therapeutics
Industry
Eligibility
4 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Stanford, California • Worcester, Massachusetts • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced May 22, 2026, 1:11 AM EDT